STA
HALO icon

Summit Trail Advisors’s Halozyme HALO Stock Holding History

Summit Trail Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569K Buy
7,267
+785
+12% +$53.5K 0.01% 1178
2026
Q1 		$419K Sell
6,482
-124
-2% -$8.74K 0.01% 1219
2025
Q4 		$445K Buy
6,606
+3,125
+90% +$210K 0.01% 1109
2025
Q3 		$255K Buy
+3,481
New +$231K ﹤0.01% 1241
2018
Q1 		– Sell
-176
Closed -$3K – 937
2017
Q4 		$3K Buy
+176
New +$3.24K ﹤0.01% 1545

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Summit Trail Advisors's HALO Position: Q2 2026 in Review

Summit Trail Advisors increased its Halozyme (HALO) stake by 12% in Q2 2026, buying an estimated $53.5K and bringing the position to 7,267 shares worth $569K. The position accounts for 0.01% of the portfolio, ranked #1178.

Summit Trail Advisors first reported a position in HALO in Q4 2017 and has held it in 5 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Summit Trail Advisors held 7,267 shares of Halozyme worth $569K as of Q2 2026.
  • Summit Trail Advisors bought 785 Halozyme shares in Q2 2026, an estimated $53.5K.
  • Halozyme made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1178 holding.
  • Summit Trail Advisors first reported a position in Halozyme in Q4 2017 and has held it in 5 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.